(0.11%) 5 186.46 points
(0.06%) 38 877 points
(-0.07%) 16 338 points
(0.04%) $78.51
(0.68%) $2.21
(-0.35%) $2 323.10
(-0.50%) $27.48
(2.38%) $987.90
(0.19%) $0.930
(0.81%) $10.91
(0.45%) $0.799
(-0.05%) $91.30
-1.90% $ 2.07
Live Chart Being Loaded With Signals
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction...
Stats | |
---|---|
Volumen de hoy | 15 681.00 |
Volumen promedio | 17 855.00 |
Capitalización de mercado | 11.35M |
EPS | $0 ( 2024-04-04 ) |
Próxima fecha de ganancias | ( $-0.400 ) 2024-06-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.690 |
ATR14 | $0.0350 (1.69%) |
Can-Fite Biopharma Ltd Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Can-Fite Biopharma Ltd Finanzas
Annual | 2023 |
Ingresos: | $743 000 |
Beneficio Bruto: | $728 001 (97.98 %) |
EPS: | $-1.790 |
FY | 2023 |
Ingresos: | $743 000 |
Beneficio Bruto: | $728 001 (97.98 %) |
EPS: | $-1.790 |
FY | 2022 |
Ingresos: | $810 000 |
Beneficio Bruto: | $810 000 (100.00 %) |
EPS: | $-3.76 |
FY | 2021 |
Ingresos: | $853 000 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.106 |
Financial Reports:
No articles found.
Can-Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico